Adding Atezolizumab to Front-Line Platinum-Based Chemotherapy Improves Progression-Free Survival in mUC
Atezolizumab administered with chemotherapy was well-tolerated in patients with metastatic urothelial cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Olaparib Outperforms Enzalutamide or Abiraterone Acetate in Men with mCRPC and HRR Alterations
A clinically meaningful benefit in radiographic progression-free survival was provided by olaparib in men with metastatic castration-resistant prostate cancer who had progressed on prior treatment with new hormonal anticancer treatments
Ivosidenib Provides Prolonged Progression-Free Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
Ivosidenib may be a new treatment option for rare cholangiocarcinoma in patients with an isocitrate dehydrogenase 1 mutation
Efficacy Differences Are Observed According to Patients’ Sex with Immunotherapy in Advanced Solid Tumours
Survival benefit following immune blockade also differs in men and women when the agent is administered as monotherapy or in combination with chemotherapy
First Report of Head and Neck Squamous Cell Carcinoma Treatment Individualised by Geriatric Assessment
Fit and unfit elderly patients derive different benefit from systemic treatment for HNSCC
Lenvatinib Provides Encouraging Responses in Advanced or Metastatic Thymic Carcinoma
Second-line treatment with lenvatinib shows promising anti-tumour activity
Adding Pembrolizumab to Neoadjuvant Chemotherapy Improves Outcome in Early TNBC
Neoadjuvant therapy with pembrolizumab plus chemotherapy provides greater anti-tumour activity than placebo plus chemotherapy in patients with early stage triple negative breast cancer
Significant PFS Benefit Observed with Veliparib plus Carboplatin and Paclitaxel in Patients with Advanced HER2-negative Breast Cancer and BRCA1/2 Mutations
Adding veliparib to carboplatin and paclitaxel doubled the 3-year progression-free survival rate over carboplatin and paclitaxel
Final FLAURA Results Demonstrate Overall Survival Benefit with Osimertinib Over TKIs in Advanced NSCLC
Exploratory analysis of FLAURA data demonstrates that longitudinal ctDNA monitoring can provide early detection of disease progression and/or resistance in advanced NSCLC
LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
The results from LIBRETTO-001 trial
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic Colorectal Cancer
TRIUMPH and MOUNTAINEER demonstrate promising clinical benefit for dual HER2 blockade in patients with HER2-amplified metastatic CRC; however, HERACLES-B did not meet the primary endpoint
First-Line Pembrolizumab Versus Chemotherapy in Patients with Advanced G/GEJ Cancer Demonstrates Similar Survival and HRQoL
A subset of patients with MSI-H tumours demonstrated superior benefit from pembrolizumab, both in combination with chemotherapy or as monotherapy